Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818187 | 0.88 | AOC3 (0.50) | KDM4EGALR3HSP90AA1NR1H4AOC3 | |
| SCHEMBL29818907 | 0.86 | AOC3 (0.46) | KDM4EGALR3HSP90AA1NR1H4AOC3 | |
| SCHEMBL2207386 | 0.86 | AOC3 (0.46) | KDM4EGALR3HSP90AA1NR1H4AOC3 | |
| SCHEMBL4568798 | 0.85 | TSHR (0.47) | KDM4EALDH1A1SMN1; SMN2GALR3HSP90AA1 | |
| SCHEMBL25823428 | 0.82 | L3MBTL1 (0.49) | KDM4ENSD2ALDH1A1SMN1; SMN2AOC3 | |
| SCHEMBL16572775 | 0.82 | CYSLTR2 (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL19407140 | 0.81 | AOC3 (0.61) | KDM4EAOC3SLC6A4 | |
| SCHEMBL13881797 | 0.81 | HTR1B (0.58) | KDM4ENSD2ALDH1A1SMN1; SMN2GALR3 | |
| SCHEMBL19291383 | 0.81 | AOC3 (0.38) | GALR3HSP90AA1NR1H4AOC3 | |
| SCHEMBL25821837 | 0.80 | KDM4E (0.46) | KDM4EAOC3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KDM4E 2227/4885NSD2 2986/4885ALDH1A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.